exendin-4 glp-1 Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons Exendin-4, a glucagon-like peptide 1

Roche data shows stomach-churning side effects of weight-loss drugs

Wen: At the moment, the understanding is that tirzepatide and semaglutide need to be taken for a lifetime

Whats Next: Regulatory filing for weight management: by end of 2025 Submission for type 2 diabetes: expected in 2026 Drug discovered by Chugai, licensed by Lilly in 2018 Implication: Orforglipron could become the first once-daily oral GLP-1 therapy with potent glucose-lowering and weight-loss benefits, potentially disrupting the injectable incretin market.

Studies such as the SUSTAIN and STEP trials have demonstrated their benefits in both glycemic control and weight reduction, positioning GLP-1 agonists as cornerstones in the treatment of metabolic disorders

This marks the first time a regulatory authority has formally recognized the link , reinforcing concerns previously raised in clinical studies

GLP-1 medicines may help control lupus inflammation, reduce stress in the blood vessels, and protect internal organs